Role of CML stem cells for the recurrence after Tyrosine kinase inhibitor therapy (IMAGE)

Hiroshima University

Role of CML stem cells for the recurrence after Tyrosine kinase inhibitor therapy

Caption

CML stem cells, which are the cellular source of the vast majority of CML cells, are reportedly resistant to TKI therapy due to the stem cell quiescence. Thus, the remaining CML stem cells are responsible for the recurrence after TKI therapy.

Credit

Kazuhito Naka, Hiroshima University

Usage Restrictions

News organizations may use or redistribute this image, with proper attribution, as part of news coverage of this paper only.

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.